Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by market... Read more

Stock Quote

PTGX (Common Stock)
$19.32 - 0.14 (0.72%)
Exchange :NASDAQ
Volume :6,243
Today's Open$19.51
Previous Close$19.46
Data as of January 18, 2018 10:21 a.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $19.32 with a 52 week high of $21.68 and a 52 week low of $8.00.

Recent Press Releases

January 04, 2018

Protagonist Therapeutics Granted Two New US Patents for Peptide Drug Candidates PTG-100 and PTG-300 read more

December 14, 2017

Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors read more

December 14, 2017

Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 read more

Upcoming Events

There are currently no events scheduled.

Presentation

Investor Presentation

Data provided by Nasdaq. Minimum 15 minutes delayed.